Why the study?
Cardiac amyloidosis is associated with a poor prognosis without treatment, making early diagnosis and management critical to increase survival.
This review highlights recent advances in diagnostic modalities and disease-modifying therapies that are improving the management and prognosis of cardiac amyloidosis.
Advances warrant clinical awareness in cardiac amyloidosis; leaves open randomized validation of emerging options.
INTRODUCTION: Cardiac amyloidosis is characterized by amyloid fibril aggregation due to misfolded circulating proteins and their deposition in the heart, leading to cardiac damage and dysfunction. Given cardiac amyloidosis is associated with a poor prognosis without treatment, early diagnosis and management are critical to increase survival from the disease. AREAS COVERED: This article provides an overview of the disease process, diagnostic modalities, and therapies for cardiac amyloidosis. EXPERT OPINION: Recent technological advances have led to the development of reliable and accurate diagnostic modalities for identifying cardiac amyloidosis. Recent introduction of novel disease-modifying therapies for cardiac amyloidosis has resulted in improvements in the management and prognosis of the disease.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: